Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04854499
Title Study of Magrolimab Combination Therapy in Participants With Head and Neck Squamous Cell Carcinoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Gilead Sciences

head and neck squamous cell carcinoma


Carboplatin + Fluorouracil + Pembrolizumab

Docetaxel + Hu5F9-G4

Cisplatin + Fluorouracil + Pembrolizumab

Hu5F9-G4 + Pembrolizumab

Carboplatin + Fluorouracil + Hu5F9-G4 + Pembrolizumab

Cisplatin + Fluorouracil + Hu5F9-G4 + Pembrolizumab

Age Groups: senior | adult
Covered Countries USA | ESP | DEU | BEL

No variant requirements are available.